Pds biotech announces pds0101 combined with chemoradiotherapy associated with rapid decline in circulating tumor dna (ctdna/cfdna)

Princeton, n.j., oct. 02, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (pds biotech or the company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced data demonstrating lead candidate pds0101 in combination with standard-of-care (soc) chemoradiotherapy (crt) was associated with a rapid decline in human papillomavirus (hpv) circulating cell-free dna (cfhpv-dna), a potential predictive biomarker of treatment response. the data from the immunocerv phase 2 clinical trial were featured in an oral presentation by aaron seo, md, phd, of the university of texas md anderson cancer center, at the american society for radiation oncology (astro 2023) annual meeting in san diego, ca.
PDSB Ratings Summary
PDSB Quant Ranking